Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSE 2101

Drug Profile

OSE 2101

Alternative Names: EP-2101; IDM 2101; OSE-2101; Tedopi

Latest Information Update: 10 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IDM Pharma
  • Developer Bristol-Myers Squibb; GERCOR; OSE Immunotherapeutics
  • Class Cancer vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 07 Feb 2019 Phase-II clinical trials in Pancreatic cancer (Monotherapy, Second-line therapy or greater, Metastatic disease) in France (SC) (NCT03806309)
  • 07 Feb 2019 Phase-II clinical trials in Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in France (SC) (NCT03806309)
  • 15 Jan 2019 OSE Immunotherapeutics receives patent allowance for OSE 2101 and its combination with neoepitopes, in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top